CLINICAL TRIALS PROFILE FOR M.V.I.-12 LYOPHILIZED
✉ Email this page to a colleague
All Clinical Trials for M.V.I.-12 LYOPHILIZED
Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
---|---|---|---|---|---|---|
NCT00024492 ↗ | Study of Liposome Encapsulated Mitoxantrone (LEM) in Patients With Advanced Cancer | Completed | INSYS Therapeutics Inc | Phase 1 | 2001-08-01 | Liposome entrapped mitoxantrone (LEM) is a mixture of commercially available mitoxantrone HCL (Novantrone) and a combination of lyophilized lipids. Mitoxantrone, the active agent in the investigational formulation, is a currently marketed chemotherapeutic agent. The rationale for development of liposomal formulations is primarily that of improving the safety profile of the drug, which may permit dose intensification and/or an increase in the cumulative dose that may be administered, resulting in enhanced efficacy. LEM will be given to patients with advanced solid tumors to determine the dose of drug these patients can tolerate. Patients will receive intravenous LEM every 21 days until the disease progresses or toxicity occurs requiring treatment discontinuation. Anti-tumor effects of LEM will be assessed and patients will be evaluated for safety and tolerability. |
NCT00111956 ↗ | Effects of Tumor Necrosis Factor (TNF)-Alpha Antagonism in Patients With Metabolic Syndrome | Completed | Massachusetts General Hospital | Phase 2/Phase 3 | 2004-04-01 | Metabolic syndrome is associated with increased inflammatory cytokines and reduced adiponectin, that may be mediated in part by TNF production from abdominal fat. We reasoned that an anti-TNF agent would reduce C-reactive protein (CRP) and increase adiponectin, improving the inflammatory milieu associated with metabolic syndrome. |
NCT00111956 ↗ | Effects of Tumor Necrosis Factor (TNF)-Alpha Antagonism in Patients With Metabolic Syndrome | Completed | National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) | Phase 2/Phase 3 | 2004-04-01 | Metabolic syndrome is associated with increased inflammatory cytokines and reduced adiponectin, that may be mediated in part by TNF production from abdominal fat. We reasoned that an anti-TNF agent would reduce C-reactive protein (CRP) and increase adiponectin, improving the inflammatory milieu associated with metabolic syndrome. |
NCT00123877 ↗ | Study of GPX-100 in the Treatment of Metastatic Breast Cancer | Terminated | Gem Pharmaceuticals | Phase 2 | 2005-03-01 | The purpose of this early Phase II multicenter trial is to determine the objective clinical response to GPX-100, an anthracycline similar to doxorubicin, in up to 40 patients with newly diagnosed metastatic breast cancer. GPX-100 is unique among anthracyclines because it is not converted to doxorubicinol during metabolism in the body. This metabolite has been shown to be a major cause of damage to the heart (cardiotoxicity) in laboratory studies. Eligible patients who are enrolled in this study will receive GPX-100 as a single agent at the beginning of as many as 8 three week long cycles of chemotherapy. Objective measurements of tumor response will be made by computed tomography (CT) scans. |
NCT00240929 ↗ | A Phase II Randomized, Double-Blind, Two-Period Cross-Over Study to Evaluate the Pharmacokinetics, Safety and Tolerability of a Liquid Formulation of Palizvizumab (MEDI-493, Synagis) | Completed | MedImmune LLC | Phase 2 | 2002-09-01 | A total of 150 children who meet the entry criteria will be randomized 1:1 to receive one of the following treatment sequence A or B. |
>Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
Clinical Trial Conditions for M.V.I.-12 LYOPHILIZED
Condition Name
Condition Name for M.V.I.-12 LYOPHILIZED | |
Intervention | Trials |
Healthy | 10 |
Aggressive Periodontitis | 2 |
Stage I Squamous Cell Carcinoma of the Lip and Oral Cavity | 2 |
Stage II Squamous Cell Carcinoma of the Oropharynx | 2 |
[disabled in preview] | 0 |
This preview shows a limited data set Subscribe for full access, or try a Trial |
Clinical Trial Locations for M.V.I.-12 LYOPHILIZED
Trials by Country
Clinical Trial Progress for M.V.I.-12 LYOPHILIZED
Clinical Trial Phase
Clinical Trial Sponsors for M.V.I.-12 LYOPHILIZED
Sponsor Name